Vytrus Biotech

Vytrus Biotech Debt

The Debt of Vytrus Biotech (VYT.MC) as of Oct 17, 2026 is 1.54 M EUR. In the previous year, Debt was 1.99 M EUR — a change of -22.50% (lower).

Debt

1.54 MEUR

YoY

-22.50%

Last updated:

In 2025, Vytrus Biotech's total debt was 1.54 M EUR, a -22.50% change from the 1.99 M EUR total debt recorded in the previous year.

The Vytrus Biotech Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
221,800.00 EUR
Jan 1, 2019
225,200.00 EUR
Jan 1, 2020
670,790.00 EUR
Jan 1, 2021
739,370.00 EUR
Jan 1, 2022
735,110.00 EUR
Jan 1, 2023
2.37 M EUR
Jan 1, 2024
1.99 M EUR
Jan 1, 2025
1.54 M EUR
The Vytrus Biotech Debt history
YEARDebtYoY
1.54 MEUR-22.50%
1.99 MEUR-15.86%
2.37 MEUR+221.98%
735,110.00EUR-0.58%
739,370.00EUR+10.22%
670,790.00EUR+197.86%
225,200.00EUR+1.53%
221,800.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vytrus Biotech Stock analysis

What does Vytrus Biotech do? Vytrus Biotech SA, based in Terrassa, Spain, develops cosmetic active ingredients using plant stem cell technology. The company, listed on 24 March 2022, focuses on creating high-value natural active ingredients for the cosmetics and pharmaceutical sectors through industrial-scale production of bioactive molecules derived from plant cell cultures. With 29 employees, Vytrus targets dermo-cosmetics, veterinary medicine, and functional food, achieving over 99% resource savings compared to traditional methods. Vytrus Biotech is one of the most popular companies on Eulerpool.

Debt Details

Understanding Vytrus Biotech's Debt Structure

Vytrus Biotech's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Vytrus Biotech's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Vytrus Biotech’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Vytrus Biotech’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Vytrus Biotech stock

Debt of Vytrus Biotech is 1.54 M EUR in 2025.

Debt of Vytrus Biotech changed from 1.99 M EUR to 1.54 M EUR, representing a -22.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Vytrus Biotech since 2006 – with annual values, charts, and detailed analysis.

Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Vytrus Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Vytrus Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vytrus Biotech